PI Institute for Hemostasis and Vascular Biology $189,406 Transfusion Research Institute (admin core) Medicine PI Hemophilia Hemostasis and Vascular Biology $136,423 Center of Research Institute-Gladwin Western PA PI Institute for $31,099 Genetic Basis of Differential Blood Transfusion Donor RBC Storage Medicine Capacity/Polymorphisms that Improve Hemoglobin and/or storage iron in high intensity blood donors Co-PI Bayer $5,730,790 A Phase IIb Randomized, Corporation Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases Co-I NHLBI R01 $11,255 Reactive Oxygen Species in Vascular HL079207 Disease Co-I NHLBI Effects of Nitric Oxide in Sickle Cell $29,333 4 R37 Blood HL058091 Co-I NHLBI U01 $114,510 Network Management Core (NEMO) HL128954 for the Pulmonary Trials Cooperative (PTC) Co-I NIGMS $154,570 Role of Erythroid DAMP Molecules in the Pathogenesis of Vascular Injury in Sepsis Co-I NHLBI $386,805 Novel Role of Smooth Muscle B5 Reductase in Sickle Cell Disease Co-I United Effect of Remodulin in Pulmonary $183,270 Therapeutics Hypertension Associated with Heart Corp. Failure with Preserved Ejection Fraction (PH-HFpEF) COMPLETED GRANT SUPPORT PI Bayer Use of sGC Activators to Bypass NO $240,029 Corporation Scavenging by Hemolysis in SCD PI United Influence of Treprostenil on RV Function $80,283 Therapeutics and Metabolism Corp. Co-I Aires A Dose Escalation Study to Evaluate the $66,982 Pharmaceuticals Effect of Inhaled Nitrite on
PI Institute for Transfusion Medicine Hemostasis and Vascular Biology Research Institute (admin core) $189,406 PI Hemophilia Center of Western PA Hemostasis and Vascular Biology Research Institute-Gladwin $136,423 PI Institute for Transfusion Medicine Genetic Basis of Differential Blood Donor RBC Storage Capacity/Polymorphisms that Improve Hemoglobin and/or storage iron in high intensity blood donors $31,099 Co-PI Bayer Corporation A Phase IIb Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases $5,730,790 Co-I NHLBI R01 HL079207 Reactive Oxygen Species in Vascular Disease $11,255 Co-I NHLBI 4 R37 HL058091 Effects of Nitric Oxide in Sickle Cell Blood $29,333 Co-I NHLBI U01 HL128954 Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) $114,510 Co-I NIGMS Role of Erythroid DAMP Molecules in the Pathogenesis of Vascular Injury in Sepsis $154,570 Co-I NHLBI Novel Role of Smooth Muscle B5 Reductase in Sickle Cell Disease $386,805 Co-I United Therapeutics Corp. Effect of Remodulin in Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) $183,270 COMPLETED GRANT SUPPORT PI Bayer Corporation Use of sGC Activators to Bypass NO Scavenging by Hemolysis in SCD $240,029 PI United Therapeutics Corp. Influence of Treprostenil on RV Function and Metabolism $80,283 Co-I Aires Pharmaceuticals A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on $66,982 Blind,
777resume.docx